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Rett syndrome (RTT) is a severe neurological disorder caused by mutations in the X-linked MECP2 gene,
which encodes a methyl-CpG binding transcriptional repressor. Using theMecp2-null mouse (an animal model
for RTT) and differential display, we found that mice with neurological symptoms overexpress the nuclear gene
for ubiquinol-cytochrome c reductase core protein 1 (Uqcrc1). Chromatin immunoprecipitation demonstrated
that MeCP2 interacts with the Uqcrc1 promoter. Uqcrc1 encodes a subunit of mitochondrial respiratory
complex III, and isolated mitochondria from theMecp2-null brain showed elevated respiration rates associated
with respiratory complex III and an overall reduction in coupling. A causal link between Uqcrc1 gene overex-
pression and enhanced complex III activity was established in neuroblastoma cells. Our findings raise the
possibility that mitochondrial dysfunction contributes to pathology of the Mecp2-null mouse and may contrib-
ute to the long-known resemblance between Rett syndrome and certain mitochondrial disorders.
Rett syndrome (RTT) is a profound neurological disorder
that almost exclusively affects girls. Approximately 80% of
patients possess a mutation in one copy of the X-linked
MECP2 gene that is, except in very rare cases, absent in so-
matic DNA from the parents (1). It follows that MECP2 mu-
tations are the underlying cause of RTT. Mice lacking an intact
Mecp2 gene have been generated in several laboratories (5, 10,
37). Without the Mecp2 gene, mice are born, but they acquire
neurological symptoms after about 6 weeks and die at about 10
weeks of age (5, 10). Females heterozygous for the disrupted
Mecp2 allele are apparently normal for several months, pro-
ducing multiple litters, but later display symptoms similar to
those of the Mecp2-null mice. An important difference is that
their health does not progressively decline but remains stable
for an apparently normal life span (10). These heterozygous
animals are genetically most comparable to RTT patients, and
their delayed-onset neurological symptoms and abnormal gait
recall the human condition. The Mecp2-null mouse therefore
provides an animal model for human RTT with the potential to
shed light on its underlying molecular causes (19).
MeCP2 is a nuclear protein that binds preferentially to
methylated sites in chromosomal DNA (22, 27, 29) and can
function as a DNA methylation-dependent transcriptional re-
pressor (27). Analyses of the Mecp2-null mouse therefore
sought genes that might be overexpressed due to an absence of
repression by MeCP2. Microarray analysis of brain RNA
showed small alterations in the levels of multiple mRNAs
when wild-type (wt) and Mecp2-null samples were compared
(38). Although the effects were insignificant for individual
genes, they became statistically significant when groups of af-
fected genes were considered. Success in finding direct targets
of MeCP2 was first achieved via a “candidate gene” approach
(6, 24). One of four promoters of the gene for brain-derived
neurotrophic factor (Bdnf) was found to bind MeCP2. This
promoter is activated by artificial stimulation of cultured mu-
rine neurons. Remarkably, MeCP2 becomes phosphorylated
upon stimulation and is lost from the promoter, thereby tem-
porarily relieving MeCP2-mediated repression. Recent studies
have additionally reported abnormal expression of the Dlx-5
and Dlx-6 (13), UBE3A and GABRB3 (35), and Sgk1 and Fkbp5
(31) genes as a target genes for MeCP2.
In an attempt to detect additional MeCP2-regulated genes
and assess their contributions to phenotype, we subjected
mRNA from Mecp2-null mouse brains to global analysis of
gene expression by using a variant of differential display (17).
Populations of mRNAs from mutant and wild-type brains were
visualized by amplifying cDNA subsets that were then dis-
played by gel electrophoresis. Reproducible differences in the
intensities of the resulting bands indicate altered expression.
Our analysis revealed that the gene encoding a component of
the mitochondrial respiratory chain is misregulated in the mu-
tants at a time when symptoms are just beginning. We hypoth-
esized that the phenotype of these mice might involve mito-
chondrial abnormalities, and we therefore investigated
mitochondrial respiration in Mecp2-null mouse brain by using
an oxygen electrode. The results showed abnormal respiration
in brain mitochondria from mutant symptomatic mice com-
pared to wild-type controls. Blue native gel electrophoresis of
respiratory complexes followed by enzymatic staining showed
reduced activity in some components of the respiratory chain.
Overexpression of the Uqcrc1 gene in cultured cells induced
physiological changes in mitochondria that resembled those
seen in the Mecp2-null mouse brain. Our data therefore raise
the possibility that some of the characteristics of the mouse
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phenotype, and perhaps of human RTT, are mitochondrial in
origin.
MATERIALS AND METHODS
RNA isolation. RNA was purified from whole brain using TRI reagent (Sigma)
according to the manufacturer’s recommendations.
ADDER differential display. Pooled total RNA (three RNA pools, each con-
sisting of three separate RNA preparations; nine brain samples in total) from
Mecp2-null male mice (C57/black backcrossed two to five times; average age, 68
days) and the same number of control littermates were used as an input for
ADDER (amplification of double-stranded cDNA end restriction fragments)
analysis. ADDER was performed as described previously (17) with minor mod-
ifications. Briefly, pooled total RNA samples were used for cDNA synthesis,
using a poly(A)-annealing oligonucleotide with a biotin label at its 5 end. cDNA
was then adsorbed on magnetic streptavidin beads and cut with MboI (NEB)
restriction endonuclease. The resulting DNA ends were ligated to oligonucleo-
tide adaptors and released from beads by AscI (NEB) digestion. cDNA frag-
ments were amplified and used as templates for differential display PCR using
primers with different terminal nucleotides (Fig. 1a). Bands with different inten-
sities were cut from the gel, and eluted DNA was PCR amplified using primers
with a specific terminal 3 dinucleotide pair. Reamplified DNA was cloned into
a plasmid vector. Restriction analysis of 24 picked clones allowed identification
of the misexpressed fragment.
Reverse transcription and real-time PCR analysis. The RNA pools were used
for cDNA synthesis as described elsewhere (18). Real-time PCR analysis was
performed using an iCycler real-time PCR machine (Bio-Rad). Four parallel
reactions were carried out for each cDNA pool with IQ SYBR green Supermix
(Bio-Rad) or homemade mix (0.5 SYBR green [Molecular Probes], 10 nM
fluorescein [Sigma], 1 PCR buffer with MgCl2 [2 mM final concentration;
Roche], and 200 M deoxynucleoside triphosphates [ABgene] with 1 U FastStart
Taq polymerase [Roche]). Results were always displayed relative to GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) cDNA. Primers used for this anal-
ysis are shown in Table 1.
Chromatin immunoprecipitation. Three whole brains (from adult mice age 2
to 5 months) provided sufficient input material for six or seven immunoprecipi-
tations. Flash-frozen brains were ground in liquid nitrogen, and the powder was
poured into fixation solution (1% formaldehyde in phosphate-buffered saline).
Fixation was continued for 15 min at room temperature and quenched with 0.125
M (final concentration) glycine solution. Pelleted cells were washed with phos-
phate-buffered saline and homogenized in a Dounce homogenizer. After cen-
trifugation, cells were resuspended in 9 ml of cell lysis buffer (0.2% NP-40, 10
mM NaCl, 10 mM Tris-HCl [pH 8], Complete [Roche] protease inhibitors).
Lysate was triturated through a 25-gauge needle to remove lumps and incubated
for 15 min with an additional 6 ml of lysis buffer. Nuclei were then harvested by
spinning at 4,000  g for 5 min and resuspended in 3.6 ml of nucleus lysis buffer
(50 mM Tris-HCl, 10 mM EDTA, 1% sodium dodecyl sulfate [SDS], protease
inhibitors). Nuclei were lysed for 10 min at room temperature and diluted with
2.2 ml of immunoprecipitation dilution buffer (1% Triton X-100, 2 mM EDTA,
150 mM NaCl, 20 mM Tris HCl [pH 8], protease inhibitors). Chromatin was
sonicated twice for 4 min with a Branson Sonifier 250 (duty cycle 60; output, 6)
to obtain chromatin DNA fragments of about 200 bp on average. Chromatin was
then cleared by centrifugation, diluted five times, precleared with protein A-
Sepharose (Amersham), and subjected to overnight immunoprecipitation with
rabbit polyclonal antibody 674 against MeCP2 (28) and rabbit polyclonal histone
H3 dimethyl K9 antibody (Abcam). Antibody precipitates were bound to protein
A-Sepharose for 1 h. Washes were performed once with TSEI (0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl [pH 8]), four times
FIG. 1. Global analysis of gene expression by ADDER reveals misexpressed genes in Mecp2-null mouse brain. (a) Top panel: primers used for
differential display PCR. Shaded bars represent constant regions with 3-terminal varied regions. Variable cDNA sequences are represented by
lines. Bottom panel: differential display gels with two bands with altered intensity that were subsequently recovered and identified as Uqcrc1
(asterisk in center panel) and mt-Nd2 (asterisk in right panel). (b) Real-time PCR data showing Uqcrc1 up-regulation in early- and late-
symptomatic mice but not in presymptomatic mice. Three pools, each containing RNA from three brains, were analyzed in quadruplicate to
generate these data. The horizontal lines represent the means, the boxes delineate the standard errors of the means, and whiskers extend the
standard deviations. , significant difference (t test, P  0.001).
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with TSEII (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 500 mM NaCl, 20 mM
Tris-HCl [pH 8]), once with buffer III (0.25 M LiCl, 1% NP-40, 1% deoxycholate,
1 mM EDTA, 10 mM Tris-HCl [pH 8]), and three times with Tris-EDTA.
Antibody precipitates were then extracted twice with extraction solution (1%
SDS, 0.1 M sodium hydrocarbonate), and cross-links were reversed overnight at
65°C. DNA was purified with the QIAGEN PCR purification kit and eluted in 50
l of elution buffer (QIAGEN). The final eluate (2 l) was used for PCRs.
Uqcrc1 promoter PCR was done with primers uq1pd (CTTCTGTGTCTCCAT
TTCCCAAG) and uq1pr (TCTGTGCAAGAAGGTGTCCAC). Bdnf pIII
primers were as described previously (6).
Mitochondrial isolation and respiration measurements. Isolated mitochon-
dria were prepared from whole brains of wt and Mecp2-null mice as described
previously (20) with modifications (2). Briefly, brains were homogenized in 5 ml
of isolation buffer (0.25 M sucrose, 10 mM MOPS [morpholinepropanesulfonic
acid], 1 mM EGTA, 1 mg/ml bovine serum albumin, pH 7.4) before dilution to
10 ml with isolation buffer and centrifugation at 2,000  g for 3 min at 4°C. The
pellet was discarded and the supernatant respun. Following removal of the pellet,
the supernatant was spun at 12,500  g for 8 min. The resultant pellet was
resuspended in 3% Ficoll in isolation buffer and was layered upon 6% Ficoll in
isolation buffer. The gradient was spun at 11,500  g for 30 min. The pellet was
resuspended in 10 ml of isolation buffer with 5 mg of digitonin/g initial brain
weight before centrifugation at 11,500  g for 10 min, removal of supernatant,
resuspension in 10 ml isolation buffer, and a further centrifugation at 11,500 
g. The final pellet was collected, resuspended in 1 ml isolation buffer, and kept
on ice.
Measurements of oxygen consumption were carried out in a polarographic
oxygen electrode (Rank Brothers Ltd.) thermostatted to 30°C. Small quantities
(50 or 100 l) of mitochondrial suspension were added to 3 ml of respiration
buffer (25 mM sucrose, 75 mM mannitol, 95 mM KCl, 20 mM Tris-HCl [pH 7.4],
5 mM KH2PO4, 50 M EDTA, 1 mg/ml bovine serum albumin) and a flat
baseline acquired prior to addition of substrates. Complex I substrates (pyruvate
and malate at final concentrations of 5 mM and 2.5 mM, respectively) were used
to assay respiratory chain activity through complexes I, III, and IV. The addition
of 8 M rotenone to inhibit complex I activity, followed by the addition of
succinate to a final concentration of 15 mM, allowed the measurement of respi-
ratory activity via complexes II, III, and IV. Complex IV activity was measured
following the addition of N,N,N,N-tetramethylphenylenediamine (TMPD) and
ascorbate to final concentrations of 80 M and 10 mM, respectively, while the
respiratory chain was blocked at complex III with 50 nM myxathiazol. The
TMPD auto-oxidation rate was found to be the same in the presence or absence
of the complex IV inhibitor KCN. TMPD rates presented were all subjected to
an auto-oxidation rate subtraction. Sufficient ADP was added to allow the ade-
quate measurement of state 3 respiration. The uncoupling protonophore car-
bonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) was added to a final
concentration of 1.6 M. Respiration data were normalized to protein concen-
trations, which were determined by Peterson’s modification of the assay of Lowry
et al. (32).
Electron microscopy. Transmission electron microscopy was performed using
standard techniques. Mitochondrial samples were fixed overnight in 2.5% glu-
taraldehyde and stained in 2% (wt/vol) osmium tetroxide for 1 h (33). Sections
were examined with a Philips CM120 Biotwin transmission electron microscope.
Mitochondrial shape and size and density of cristae were scored before revealing
the genotypes.
Bisulfite DNA modification. Bisulfite DNA modification was performed using
standard procedures. Briefly, 1 g of whole-brain genomic DNA was digested
with BamHI (NEB) restriction endonuclease, denatured at 100°C for 5 min, and
incubated with 0.3 M NaOH (final concentration) for 20 min. After addition of
10 volumes of bisulfite/hydroquinone mix (0.51 g/ml sodium hydrogensulfite
[Aldrich, no. 24 397-3), 0.11 g/ml hydroquinone (Sigma, no. H9003), and 0.4 M
NaOH), the solution was overlaid with mineral oil and incubated for 5 h at 55°C.
Bisulfite-treated DNA was precipitated with isopropanol (with 50 g of glyco-
gen), desulfonated with NaOH (0.3 M final concentration) for 15 min at 37°C,
purified, and amplified by PCR. Primers for amplification (ubisd [AAATTATT
TTTATATTGTTTTTTTT] and ubisr [AAACCCTTCATCTAATCCCATCTA])
were designed with Methprimer (23). PCR-amplified DNA was cloned using a
TOPO cloning kit (Invitrogen). Data in the paper were derived from sequencing
14 or 15 clones.
Blue native electrophoresis and histochemical staining. Blue native electro-
phoresis was performed as described elsewhere (36). Briefly, to solubilize respi-
ratory complexes, equal protein amounts of purified mitochondrial sample were
supplied with 3.5 volumes of buffer C (1 M aminohexanoic acid, 50 mM BisTris-
HCl [pH 7.0]) and 1 volume of 10% dodecylmaltoside. The samples were cen-
trifuged at 100,000  g for 15 min. The supernatant protein concentration was
measured using a Bio-Rad Dc kit. The samples were then supplemented with
1/10 volume of 5% Serva Blue G in 1 M aminohexanoic acid and loaded (90 g
of protein per lane) on a gradient (5 to 13%) native polyacrylamide gel. Catalytic
staining was performed as described previously (39). Briefly, to stain for complex
I (NADH) activity, the gel was incubated in a solution containing 2 mM Tris-HCl
(pH 7.4), 0.1 mg/ml NADH, and 2.5 mg/ml nitroblue tetrazolium on a shaking
platform until the gel developed maximal staining. Complex IV activity was
evaluated in 25 ml of solution containing 12.5 mg 3,3-diaminobenzidine tetra-
hydrochloride, 0.05 M phosphate buffer (pH 7.4), 20 g/ml catalase, 25 mg
cytochrome c, and 1.87 mg sucrose. After staining, the gels were fixed in 50%
methanol and 10% acetic acid for 15 min.
Production and analysis of Uqcrc1-overexpressing cells. N2A cells were cul-
tured in Dulbecco modified Eagle medium plus 10% fetal calf serum plus
nonessential amino acids (Invitrogen). The mouse Uqcrc1 coding sequence was
PCR amplified from cDNA (Clontech MARATHON Ready mouse 11-day em-
bryo cDNA) and cloned into pBABE Puro (EcoRI, SalI) plasmid. The resulting
clone was confirmed by sequencing and transfected into the Phoenix Eco retro-
virus packaging cell line by using calcium phosphate. Viral supernatant was
collected 2 days after transfection and used to infect N2A cells in the presence
of 4 g/ml Polybrene. Puromycin (3 g/ml) was applied 48 h after infection and
maintained during cell culture. The medium was replaced with puromycin-free
medium 24 h before respiration measurements. For Western blotting, cells were
boiled in SDS loading buffer and proteins were resolved on a 10% SDS-polyac-
rylamide gel. Uqcrc1 and porin proteins were detected simultaneously using
mouse monoclonal antibodies (anti-Uqcrc1, Molecular Probes A21362; anti-
porin, Molecular Probes A31855).
Measurements of mitochondrial respiration in neuroblastoma cells. Mito-
chondrial oxygen consumption was measured in permeabilized neuroblastoma
(N2A) cells essentially by the method of Hofhaus et al. (12). Cells were harvested
by trypsinization, diluted 1:5 in medium A (250 mM sucrose, 10 mM MgCl2, 20
mM HEPES [pH 7.1]), and spun down at 250 g for 2 min. Recovered cells were
resuspended in 1 ml medium A plus 1 ml of 200 g/ml digitonin. Cells were
incubated at 37°C for 1 min prior to a 1/10 dilution in medium A and spun down
TABLE 1. Primers used for real-time PCR analysis
Gene accession no. Gene Forward primer Reverse primer
XM_146892 GAPDH gene TACCCCCAATGTGTCCGTCG CCTGCTTCACCACCTTCTTG
NM_025407 Uqcrc1 ACGGTGGGAGTGTGGATTGAC CATTGCCAGGCCGATTCTTTG
AK087448 Unknown, cDNA GCATATCAAGTGCATATCAAGTG CTTAAATTAGTTTGCTTTGCTTG
BC028971 Gtl2/Meg3 TGCAGCGGAGAGCCATAAATAAC ACATCGCCTCCCTCCCTCGTG
AK011516 Hist1h2bc GATACTAGCAGATTAACCACCAT TTCTTATCACAAATTTCTACAGT
AK034339 Unknown, cDNA GCCTATCATGCAGACCACAG GCTCGCAGGTAAGGATGTAG
AU018611 mt-Nd2 GGGCATGAGGAGGACTTAACCAAAC TGAGGTTGAGTAGAGTGAGGGATGG
NM_175092 Rhof GTCCCAAGCCCACTGTTTCTG TTGATGCCTGTGTTCTCCTGATAG
AK049648 Unknown, cDNA AGTTCCAGAATAACCGCTCTCC CTCTCTCACCCATCTGATACCTTAG
AK029199 Cdon TCCCAGTGGTAGCCTCTTATCC ATTGGTGCCACACTGTCCTTG
BC025130 Ccl19 GAGCCCTGTGTCTTGAGTAAAG ACTTGGCTGGGTTAGGTCTG
BC058513 Snrp70 GCTGACTGGTGGGAGTGTGAG TGCCATCTGCGTGCTTGTAAG
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at 250  g for 3 min. The final pellet was resuspended in 1 ml medium A and
triturated using five passes through a fire-polished glass pipette to separate the
cells. Cell counts were performed in triplicate for each sample, using a hemo-
cytometer. Cell viability was tested using trypan blue. Typically 95% of cells
stained with trypan blue following digitonin permeabilization. Permeabilized
cells (4  106) were introduced into the electrode chamber to a final volume of
3 ml in N2A respiration buffer (medium A supplemented with 1 mM ADP and
2 mM KH2PO4). Following acquisition of a stable baseline, the complex I
substrates pyruvate and malate were added (to concentrations of 5 mM and 2.5
mM, respectively) before complex I was inhibited by addition of rotenone (2
M). The complex II substrate succinate was then added (15 mM) and respira-
tion measured before maximal inhibition of the chain at complex III by using
myxathiazol (50 nM). Finally, the complex IV substrate TMPD (80 M) was
added together with ascorbate (10 mM) and a rate determined prior to complete
inhibition of the chain at complex IV by addition of KCN (1 mM).
RESULTS
Detection of misregulated genes by differential display.
Mecp2-null mice are normal at birth but develop symptoms at
around 6 weeks of age, leading to death after approximately 10
weeks (5, 10). As the time of onset of these phenotypic effects
shows considerable variability among individuals, we selected
mice according to symptom stage rather than chronological
age, using the criteria shown in Table 2. In order to maximize
our ability to detect alterations in the expression of low-abun-
dance transcripts, we compared mRNA populations in mutant
and wt brains by using a variant of differential display called
ADDER (17). We detected as broad a range of mRNAs as
possible by using multiple primer sets covering all possible
nucleotide combinations flanking the 3 poly(A) and 5 adap-
tors of the mRNA. ADDER is reported to detect transcripts
present at 10 copies per cell and to be sensitive to small
differences in RNA levels (17). We performed ADDER on
three pools (three brains per pool) of total RNA from brains of
“late-symptomatic” Mecp2-null mice (Table 2), using as con-
trols three equivalent pools from brains of wt littermates. In
total, we used 192 primer combinations, theoretically allowing
detection of about 10,000 RNA species. We observed 39 bands
that were more intense in Mecp2-null samples than in the wt
and 11 bands that were less intense. Bands corresponding to 36
nonrepetitive genes were recovered and tested for aberrant
gene expression by quantitative real-time PCR. Significant de-
regulation of gene expression in late-symptomatic brains was
verified for 12 genes (Table 3). We next asked whether these
genes are aberrantly expressed in Mecp2-null mice that had
only recently begun to display symptoms (“early-symptomatic”
mice [Table 2]). Quantitative PCR on three pools of Mecp2-
null brains (three brains per pool) revealed 3 out of the 12
genes to be misexpressed in brains of early-symptomatic mice,
in comparison with age-matched controls (t test, P  0.05). All
of the identified genes were expressed apparently normally in
presymptomatic Mecp2-null brain RNA (Table 3).
The three genes that were misexpressed in early symptom-
atic animals were considered more likely to be primary con-
TABLE 2. Classification of Mecp2-null mice according to the
manifestation of phenotype
Symptom stage
Manifestation of phenotype
Age
(days)aClasping Inertia Tremor Weightloss LOC
b
Presymptomatic      30
Early symptomatic /     55
Late symptomatic      70
a Average age of mice displaying the symptoms.
b LOC, loss of condition.
TABLE 3. Genes found by a variant of differential display and confirmed by real-time PCR
Gene
accession no. Gene (protein or comment)
Valuea for the following symptom stage and strain:
Presymptomatic Early symptomatic Late symptomatic
wt Null
P
wt Null
P
wt Null
P
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
NM_025407 Uqcrc1(ubiquinol-cytochrome
c reductase core protein 1)
1.00 0.15 1.10 0.30 0.32 1.00 0.12 1.22 0.09 <0.001 1.00 0.28 1.73 0.56 <0.001
AK087448 Unknown (contains SAM
domain)
1.00 0.16 0.96 0.12 0.28 1.00 0.28 0.69 0.10 0.004
BC028971 Gtl2/Meg3 (imprinted,
maternally expressed)
1.00 0.42 1.14 0.37 0.42 1.00 0.22 1.69 0.33 <0.001
AK011516 Hist1h2bc (histone 1 H2bc) 1.00 0.37 1.00 0.21 0.95 1.00 0.37 0.82 0.25 0.17 1.00 0.34 0.44 0.16 <0.001
AK034339 Unknown (similar to esterase/
lipase/thioesterase family
members)
1.00 0.25 1.05 0.20 0.49 1.00 0.23 1.37 0.50 0.039 1.00 0.26 1.35 0.47 0.038
AU018611 mt-Nd2 (NADH
dehydrogenase 2)
1.00 0.16 1.14 0.30 0.16 1.00 0.44 0.73 0.25 0.08 1.00 0.17 0.6 0.08 <0.001
NM_175092 Rhof (ras homolog gene
family, member f)
1.00 0.65 1.44 0.64 0.12 1.00 0.33 0.67 0.29 0.02
AK049648 Unknown 1.00 0.15 1.13 0.32 0.26 1.00 0.46 2.07 0.96 0.002 1.00 0.34 1.39 0.34 0.01
AK029199 Cdon (cell adhesion molecule-
related/down-regulated by
oncogenes)
1.00 0.25 0.89 0.23 0.31 1.00 0.16 1.39 0.23 <0.001
BC025130 Ccl19 (chemokine 	C-C motif

ligand 19)
1.00 0.40 1.00 0.30 0.96 1.00 0.21 2.69 0.71 <0.001
BC058513 Snrp70 (U1 small nuclear
ribonucleoprotein
polypeptide A)
1.00 0.42 1.40 0.59 0.08 1.00 0.38 1.44 0.57 0.04
a Mean values are normalized against the GAPDH gene and expressed relative to wt values. Significance was determined by the Student t test. Boldface indicates
genes that are significantly up-regulated (P  0.05).
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tributors to the observed pathology than those expressed only
in terminally ill animals. One of the three genes is a putative
member of the esterase/lipase/thioesterase gene family. This
gene is expressed in several tissues and has 43% amino acid
sequence identity with arylacetamide deacetylase, which plays
a role in lipid metabolism. A second gene was of unknown
function, as no annotated relatives could be detected. In this
study, we focused on the third early misexpressed gene, which
encodes Uqcrc1, a core subunit of complex III which is part of
the mitochondrial electron transport chain. Interestingly, the
gene for NADH dehydrogenase subunit 2 (mt-Nd2), another
component of the mitochondrial electron transport chain
(complex I), was found among the 11 genes that were misregu-
lated in late-symptomatic animals. Uqcrc1, a nucleus-encoded
gene, was significantly up-regulated in early- and late-symptom-
atic brains, whereas mitochondrially encoded mt-Nd2 was sig-
nificantly down-regulated in late-symptomatic, but not early-
symptomatic, brains (Fig. 1a and b; Table 3). We have failed to
detect any difference between the amounts of Uqcrc1 protein
present in the brains of Mecp2-null (early- and late-symptom-
atic) mice and wt littermates by Western blotting (data not
shown; see Discussion).
There are several possible reasons why the set of genes
detected by differential display did not overlap with those re-
ported in previous studies. Theoretically ADDER permits ex-
pression analysis of about 80% of polyadenylated transcripts,
but in practice this number is considerably lower. Our best
estimate was that we examined expression of up to 10,000
transcription units, which is around half of the total number of
expressed sequences in mouse brain and may therefore exclude
some reported targets. An additional limitation of the tech-
nique is that the PCR amplification step may be unrepresen-
tative, leaving some genes undetected. The microarray exper-
iment performed by Nuber et al. (31) utilized an array of
13,000 genes (about 60% of the expected total), and changes of
less than twofold were disregarded. As most of the genes found
by ADDER differential display are misregulated less than two-
fold, they may be missed by the microarray data analysis. Re-
examining the microarray data set, we found that Gtl2/Meg3
shows up-regulation of 1.6-fold. This gene therefore is found in
both analyses.
MeCP2 binds to the Uqcrc1 promoter in vivo. The delayed
onset of Uqcrc1 up-regulation may mean that misexpression is
an indirect consequence of the absence of MeCP2. However,
the amount of MeCP2 in neurons is known to increase dra-
matically as neurons mature (15, 26), and therefore some
genes that are not initially affected by MeCP2 may come under
its regulatory influence as MeCP2 becomes more abundant.
The increase in the concentration of MeCP2 in murine brain
occurs progressively during postnatal life as synaptogenesis
proceeds and neurons mature (16, 26). If Uqcrc1 is a direct
target, MeCP2 should bind in the vicinity of its promoter. This
prediction was verified by chromatin immunoprecipitation,
which showed that an anti-MeCP2 antibody could precipitate a
DNA region near the Uqcrc1 transcription start site (Fig. 2).
This region was not detected when Mecp2-null brain nuclei
were subjected to immunoprecipitation, thereby eliminating
the possibility of nonspecific cross-reaction of the antibody
with other nuclear components (Fig. 2b). A known MeCP2
binding site, promoter III of the Bdnf gene (6, 24), served as a
positive control for the immunoprecipitation reaction. To con-
trol for the equivalence of Mecp2-null brain chromatin prepa-
rations, we found that an antibody against dimethylated lysine
9 of histone H3 gave identical recovery of the Uqcrc1 promoter
region in Mecp2-null and wt brain nuclei. We also tested for
the presence of methyl-CpG sites in the region that appeared
to bind MeCP2 by using bisulfite sequencing. One of a group
of CpGs flanking the Uqcrc1 promoter CpG island was found
to be 33% methylated in total brain DNA (Fig. 2a). We con-
clude that MeCP2 is associated with the Uqcrc1 gene in brain
and may directly influence its expression, although we cannot
exclude the possibility that Uqcrc1 overexpression is an indi-
rect consequence of MeCP2 deficiency.
Mitochondrial abnormalities in the Mecp2-null mouse
brain. We speculated that the abnormal expression of Uqcrc1
in symptomatic Mecp2-null mice might affect mitochondrial
morphology and/or physiology. Initial examination of purified
mitochondria by electron microscopy did not reveal gross struc-
tural differences between wt and Mecp2-null mice (Fig. 3a).
We therefore performed a polarographic oxygen electrode
study to evaluate the activities of different complexes within
the electron transport chain (Fig. 3b). The protonophore
FCCP uncouples the activity of complexes I to IV from the
rate-limiting electrochemical proton gradient, thereby per-
mitting maximal activity. Symptomatic Mecp2-null mito-
chondrial samples consistently showed increased uncoupled
respiration rates when substrates were fed into the respira-
tory chain upstream of complex III (Fig. 3c, PM and Succ.)
FIG. 2. MeCP2 binds the promoter region of the Uqcrc1 gene. (a)
Uqcrc1 promoter map showing CpG frequency, methylation status, and
the region used for PCR amplification of immunoprecipitated DNA.
(b) Chromatin immunoprecipitation reveals MeCP2 bound to the
Uqcrc1 promoter in wt mouse brain but not in Mecp2-null mouse brain.
Bdnf promoter III is a positive control. DNA is specifically immuno-
precipitated with MeCP2 antibody but not with rabbit serum. No DNA
is precipitated from Mecp2-null mouse brain by anti-MeCP2 antibody.
Chromatin quality is similar in wt and Mecp2-null mouse brains, be-
cause anti-dimethyl H3 K9 antibody is able to precipitate similar
amounts of DNA.
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but not with a substrate entering downstream of complex III
(Fig. 3c, TMPD). This difference was not seen in brain
mitochondria from presymptomatic mice (Fig. 3c, left
panel). The data suggest that in symptomatic Mecp2-null
mice the maximal capacity of the respiratory chain upstream
of complex IV is increased. This is confirmed by the obser-
vation that differences in state 3 respiration rates between
symptomatic Mecp2-null and wt mice were also observed
only for substrates that feed in to the respiratory chain
upstream of complex IV (Fig. 3f).
Under physiological conditions, the proton translocation as-
sociated with complexes I, III, and IV works against an elec-
trochemical proton gradient, providing a mechanism for respi-
ratory control. The coupled states 2 and 4 represent this
condition. Increases in state 2 and 4 oxygen consumption were
observed between symptomatic Mecp2-null and wt mitochon-
FIG. 3. Investigation of the respiratory chain in mitochondria isolated from whole brains of wt and Mecp2-null mice. (a) Electron micrographs
showing isolated mitochondria from a symptomatic Mecp2-null (KO) mouse and an age-matched wt littermate. Bar, 2 m. (b) Typical output traces
from a polarographic oxygen electrode. Initially mitochondria consume very little oxygen, but following the addition of substrates, oxygen
consumption is moderately increased (state 2). Addition of ADP (state 3) permits rapid respiration, during which the proton gradient is relieved
via ATP synthase. Following phosphorylation of all the ADP present, respiration slows again (state 4). At this point, mitochondria were directly
uncoupled via the addition of the protonophore FCCP, allowing the proton pumps to run freely. (c to h) Each pair of bars shows respiration rates
using one of three different substrates: pyruvate plus malate (PM), succinate (Succ.), or TMPD (see Materials and Methods). Panels c, d, e, and
f compare respiration rates during the different respiratory states from brain mitochondria isolated from presymptomatic Mecp2-null animals (light
bars; n  8 runs with separate mitochondrial preparations derived from four animals) and age-matched wt littermate controls (dark bars). Data
from symptomatic Mecp2-null mouse mitochondria (n  16 runs with preparations from eight animals) compared to wt controls are shown at the
right in each panel. Significantly increased respiration rates were observed in mitochondria from symptomatic Mecp2-null animals with complex
I substrates (PM) and the complex II substrate (Succ.) for all respiratory states. All comparisons were tested with the t test. , P  0.05; , P 
0.01; , represent P  0.001. (g) Calculated ATP/O ratios for presymptomatic and postsymptomatic Mecp2-null animals and wt controls. No
significant differences were observed with any of the substrates. (h) Calculated respiratory control (RC) ratios for presymptomatic and postsymp-
tomatic Mecp2-null animals and wt controls. Significant decreases were observed in symptomatic Mecp2-null animals compared to wt controls for
complex I (P  0.05) and complex II (P  0.001) substrates only. Error bars indicate standard deviations.
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dria when substrates were fed in at complexes I and II but not
when these were bypassed by addition of a complex IV sub-
strate (Fig. 3d and e). Again, these differences were not seen in
presymptomatic mice.
Measurement of the amount of oxygen consumed during the
conversion of a known amount of ADP (during state 3) allows
the calculation of the ATP/O ratio. This relates the stoichi-
ometries of protons translocated per electron flowing down the
respiratory chain to the number of protons flowing through the
ATP synthase per ATP molecule produced. No significant dif-
ferences were observed in any of the measured ATP/O ratios
(Fig. 3g), implying that the respiration rate differences re-
ported above were not the result of a change in the respiratory
chain proton pumps or the efficiency of ATP synthase.
Our results show that respiration rates for symptomatic
Mecp2-null animals are significantly increased relative to those
for wt controls for all substrates that feed in upstream of
complex IV. Examination of the respiratory control ratios in-
dicates that the rates of coupled respiration have increased
proportionally more than the uncoupled rates (Fig. 3h). This
probably indicates an increase in the non-Ohmic proton con-
ductance across the mitochondrial inner membrane (30). To
maintain the proton gradient against this background “leak,”
the electron transport chain works faster and therefore con-
sumes more oxygen. Thus, mitochondria from symptomatic
mutants appear to have an overall greater respiratory capacity
(Fig. 3c) but also appear to work less efficiently (Fig. 3e and h).
Complexes I and II transfer electrons independently to com-
plex III via a common pool of ubiquinone. Despite the inde-
pendent nature of the electron paths, the observed genotype-
specific respiratory effects were similar with substrates specific
for either complex. The common link between the two path-
ways is complex III. We could not rule out the possibility,
however, that the observations are due to elevated activities of
both complexes I and II. We tested this possibility for complex
I by using blue native electrophoresis, which allows activity-
based visualization of each respiratory complex (36). Coomas-
sie blue staining of respiratory complexes from wt and Mecp2-
null mouse brains showed apparently normal levels (Fig. 4a
and data not shown). We next assayed the enzymatic activi-
ties of complexes I and IV in the gel by using histochemical
staining for NADH dehydrogenase and cytochrome oxidase
(39). Complexes I and IV each produced a single band of the
expected size (Fig. 4b and c). Samples derived from three
wild-type and mutant littermate pairs were quantified using
densitometry. The results showed that complex I activity was
indistinguishable between wt and mutant brain mitochon-
dria (t test. P  0.05). This result argues against the possi-
bility that complex I is responsible for the increase in res-
piration rates and therefore further implicates complex III.
As there is currently no in-gel assay for complex III activity,
this hypothesis was not directly testable. An interesting by-
product of the blue native electrophoresis analysis was the
discovery of a reproducible decrease in the activity of com-
plex IV (t test, P  0.001) in samples derived from Mecp2-null
mouse brains (Fig. 4d).
Uqcrc1 overexpression causes abnormal mitochondrial res-
piration in N2A cells. Multiple events could potentially cause
the mitochondrial respiration abnormalities in Mecp2-null
mouse brain described above. The simplest hypothesis, how-
FIG. 4. Analysis of the respiratory complexes by blue native electrophoresis. (a) Coomassie blue-stained blue native electrophoresis gel shows
resolved mitochondrial respiratory complexes. (b and c) Enzymatic staining of complexes I and IV, respectively. Samples from littermates are
beside each other. The stained band is highlighted with thicker arrows. (d) Statistical analysis of the enzymatic staining. Three experiments were
done with three pairs of mice, and data were evaluated using the t test. Complex IV staining in Mecp2-null mice is significantly lower (P  0.001),
while complex I staining is the same (P  0.38). Error bars show standard deviations.
VOL. 26, 2006 MITOCHONDRIAL ABNORMALITIES IN A MOUSE MODEL OF RTT 5039
ever, is that overexpression of Uqcrc1 alone is responsible for
the measured increase in oxygen consumption with complex I
and II substrates. To test this hypothesis, we overexpressed
Uqcrc1 in neuroblastoma cells. The Uqcrc1 gene was intro-
duced into mouse N2A cells by using retroviral infection, and
infected cells were maintained and expanded by selecting for
the vector-carried puromycin resistance gene. Stable Uqcrc1-
overexpressing cell lines produced 2.8 times more RNA and
1.6 times more Uqcrc1 protein than the control cells infected
with vector only (Fig. 5a and b). Permeabilized cell suspensions
of Uqcrc1-overexpressing N2A cells and control cells were then
used for respiration analysis with a Clarke oxygen electrode as
described above. When substrates upstream of complex III
were used (Fig. 5c, pyruvate/malate and succinate), we ob-
served a significant increase in the uncoupled respiration rate
in the Uqcrc1-overexpressing cell line (t test, Ppy/mal  0.001
and Psucc  0.05; n  19). Respiration rates with a complex IV
substrate (Fig. 5c, TMPD/ascorbate) resulted in similar rates
of oxygen consumption in both cell lines (t test, P  0.05).
Thus, artificial overexpression of Uqcrc1 strikingly reproduces
the data obtained with isolated uncoupled mitochondria from
the brains of Mecp2-null mice discussed above (compare Fig. 3
and 5).
DISCUSSION
Relationship of Uqcrc1 overexpression to mitochondrial ab-
normalities. The data presented here show that MeCP2 binds
to the promoter of the Uqcrc1 gene in vivo and that Uqcrc1
mRNA expression is elevated in brains of Mecp2-null mice that
have acquired neurological symptoms. Uqcrc1 up-regulation
correlates positively with symptom severity and with a signifi-
cant increase in mitochondrial respiratory capacity and a re-
duction in respiratory efficiency. The defect appears to be
associated with respiratory complex III, which contains the
Uqcrc1 protein, as increased respiration was seen when appro-
priate substrates were provided to either complex I or complex
II. Blue native electrophoresis showed normal levels of com-
plex I activity in the mutant, indicating that this complex is not
responsible for the observed increase in respiration. As these
findings implicated complex III as the source of enhanced
respiratory activity, we asked whether overexpression of
Uqrcrc1 alone is sufficient to increase mitochondrial respira-
tion. Indeed, a cell line overexpressing Uqcrc1 showed in-
creased respiration rates with substrates upstream of complex
IV. This argues that the mitochondrial respiratory abnormal-
ities seen in Mecp2-null brain are a consequence of Uqcrc1
overexpression.
Although the evidence strongly supports a causal relation-
ship between Uqcrc1 overexpression and abnormalities in mi-
tochondrial respiration, we have not been able to detect reli-
able increases in brain Uqcrc1 protein due to the 1.7-fold
increase in Uqcrc1 mRNA in the symptomatic Mecp2-null
brain. Two possible explanations for this discrepancy can be
considered: (i) Uqcrc1 may be subject to tight posttranscrip-
tional regulation, for example, by feedback modulation of
mRNA translation efficiency or by degradation of excess un-
assembled protein, or (ii) Western blotting may be insensitive
to quantitative changes of such low magnitude. The finding
that a 2.8-fold up-regulation of Uqcrc1 mRNA in N2A cells led
to only a 1.6-fold up-regulation of protein is relevant. A com-
parable ratio of excess mRNA to excess protein in the brain
samples would lead to a 1.2-fold increase in Uqcrc1 protein,
which would be difficult to detect by Western blotting.
While the molecular origin of these respiratory abnormali-
ties remains unclear, we speculate that the exquisite sensitivity
of mitochondrial assembly to the stoichiometry of its consti-
tuent proteins is responsible. For example, increased amounts
of Uqcrc1 may destabilize complex III assembly, leading to
faster electron transfer or perhaps transfer by Uqcrc1 alone.
Another possibility is that Uqcrc1 interacts with a complex III
inhibitor, which would be titrated by excess Uqcrc1. In the
structure of complex III (cytochrome bc1), Uqcrc1 is orien-
tated towards the matrix, which might allow interactions of
this kind (14).
Our studies uncovered other mitochondrial defects in the
Mecp2-null mouse brain: (i) significantly elevated coupled res-
FIG. 5. Overexpression of Uqcrc1 in an N2A cell line causes in-
creased mitochondrial respiration. (a) Real-time PCR analysis of
Uqcrc1 mRNA expression relative to GAPDH. Uqcrc1 expression in
control cell line was normalized to 1. (b) Representative Western blot
of whole-cell lysates from control and Uqcrc1-overexpressing N2A
cells. Porin serves as a loading control. Statistical analysis of duplicate
experiments indicates 1.6-fold overexpression of Uqcrc1 protein. (c)
Oxygen electrode data for the ADP-uncoupled respiration rates of
permeabilized control and Uqcrc1-overexpressing cells in the presence
of pyruvate/malate, succinate, or TMPD/ascorbate as respiratory sub-
strates. Significance was tested using the t test. , P  0.01; , P 
0.05. Error bars indicate standard deviations.
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piration rates, suggesting increased proton conductance across
the inner mitochondrial membrane; (ii) reduced activity of
cytochrome oxidase, implying a defect in complex IV; and (iii)
down-regulation of mRNA for NADH dehydrogenase, a mi-
tochondrially encoded component of complex I, in late symp-
tomatic animals. The observed increase in coupled respiration
of up to 30% indicates a loss of respiratory control which may
have a significant impact on mitochondrial efficiency in the
Mecp2-null mice. The other changes are subtle (2-fold) but
may reflect suboptimal mitochondrial performance in brains of
symptomatic Mecp2-null mice. Whether these effects are re-
lated to Uqcrc1 overexpression or arise independently is not
currently known.
Mitochondrial abnormalities and RTT. The notion that mi-
tochondrial abnormalities play a role in RTT predates the
discovery of the genetic origin of the condition. With the re-
alization that MeCP2, a nuclear transcriptional repressor, is
mutated in RTT, the mitochondrial link became less compel-
ling. It was recently noted, however, that a patient with symp-
toms normally associated with mitochondrial disorders (hypo-
tonia, small stature, developmental delay, and a slight decrease
in respiratory chain enzyme activity) harbored mutations in the
MECP2 gene (11). This overlap between symptoms of RTT
and mitochondrial disorders recalls early reports of structural
abnormalities (4, 8, 9, 34) and defects in the electron transport
chain (7, 8) in mitochondria from skin and muscle biopsies of
RTT patients. Moreover, about half of RTT patients were
reported to have elevated levels of circulatory lactic or pyruvic
acid, which might be caused by defects in the efficiency of the
respiratory chain and urea cycle complexes, both of which are
mitochondrial (21, 25).
In humans many disorders affecting the brain are due to
mutations in nuclear or mitochondrially encoded components
of the mitochondrion, sometimes resulting in increased oxida-
tive stress or induction of neuronal apoptosis. As Rett syn-
drome is not a neurodegenerative disorder (3), any contribu-
tion of mitochondrial dysfunction to RTT symptoms may take
the form of chronic mitochondrial underperformance, rather
than catastrophic failure leading to neuronal death. The changes
that we have observed in the mouse model of RTT appear to
meet this criterion, as they are small in magnitude and may
therefore compromise brain function without precipitating cel-
lular death. Future work will probe the involvement of MeCP2
in the expression of proteins that are targeted to the mitochon-
drion and will test the hypothesis that aberrant mitochondrial
function as seen in mice has a role to play in RTT.
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